Rare cancers are not so rare: The rare cancer burden in Europe

Gemma Gatta a,*, Jan Maarten van der Zwan b, Paolo G. Casali c, Sabine Siesling b, Angelo Paolo Dei Tos d, Ian Kunkler e, Renée Otter b, Lisa Licitra f, Sandra Mallone g, Andrea Tavilla g, Annalisa Trama a, Riccardo Capocaccia g, The RARECARE working group

a Department of Preventive and Predictive Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
b North East Netherlands Cancer Registry, Comprehensive Cancer Centre North East, P.O. Box 330, 9700 AH Groningen, The Netherlands
c Department of Cancer Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
d Department of Pathology, General Hospital of Treviso, Via Bordo Cavalli 42, 31100 Treviso, Italy
e Department of Clinical Oncology, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK
f Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
g Department of Cancer Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy

ARTICLE INFO

Keywords: Rare cancers Cancer registries Incidence Prevalence Survival

ABSTRACT

Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases.

Materials and methods: RARECARE analysed population-based cancer registry (CR) data on European patients diagnosed from 1988 to 2002, with vital status information available up to 31st December 2003 (latest date for which most CRs had verified data). The mean population covered was about 162,000,000. Cancer incidence and survival rates for 1995–2002 and prevalence at 1st January 2003 were estimated.

Results: Based on the RARECARE definition (incidence <6/100,000/year), the estimated annual incidence rate of all rare cancers in Europe was about 108 per 100,000, corresponding to 541,000 new diagnoses annually or 22% of all cancer diagnoses. Five-year relative survival was on average worse for rare cancers (47%) than common cancers (65%). About 4,300,000 patients are living today in the European Union with a diagnosis of a rare cancer, 24% of the total cancer prevalence.

Conclusion: Our estimates of the rare cancer burden in Europe provide the first indication of the size of the public health problem due to these diseases and constitute a useful base for further research. Centres of excellence for rare cancers or groups of rare cancers could provide the necessary organisational structure and critical mass for carrying out clinical trials and developing alternative approaches to clinical experimentation for these cancers.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

There is no internationally agreed definition of rare cancers. In Europe rare diseases are often defined as those with a prevalence of <50/100,000.1 In the US, the Orphan Drug Act defined rare diseases as those affecting <200,000 persons.2 However, a recent analysis of rare cancers in the US employed the definition of <15 incident cases per 100,000 per year.3

* Corresponding author: Address: Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Tel.: +39 02 23903518; fax: +39 02 23903522.
E-mail address: gemma.gatta@istitutotumori.mi.it (G. Gatta).
0959-8049/$ - see front matter © 2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2011.08.008

Please cite this article in press as: Gatta G et al., Rare cancers are not so rare: The rare cancer burden in Europe, Eur J Cancer (2011), doi:10.1016/j.ejca.2011.08.008